Analysis of Liquidity Ratios
Quarterly Data
Liquidity ratios measure the company ability to meet its short-term obligations.
Liquidity Ratios (Summary)
Zoetis Inc., liquidity ratios (quarterly data)
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
| Liquidity ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Zoetis Inc. current ratio deteriorated from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Zoetis Inc. quick ratio deteriorated from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Zoetis Inc. cash ratio deteriorated from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |
Current Ratio
Zoetis Inc., current ratio calculation (quarterly data)
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Current assets | 6,837) | 6,930) | 6,682) | 7,048) | 6,794) | 6,611) | 6,757) | 6,285) | 4,772) | 4,748) | 4,618) | 4,484) | 4,379) | 4,399) | 4,076) | 4,239) | 4,267) | 4,217) | 4,894) | 3,584) | 3,383) | |||||||
| Current liabilities | 3,034) | 1,797) | 1,471) | 2,091) | 2,066) | 2,170) | 2,400) | 1,811) | 1,721) | 1,806) | 1,052) | 1,075) | 1,082) | 1,223) | 1,003) | 967) | 1,000) | 1,094) | 1,746) | 1,784) | 1,730) | |||||||
| Liquidity Ratio | ||||||||||||||||||||||||||||
| Current ratio1 | 2.25 | 3.86 | 4.54 | 3.37 | 3.29 | 3.05 | 2.82 | 3.47 | 2.77 | 2.63 | 4.39 | 4.17 | 4.05 | 3.60 | 4.06 | 4.38 | 4.27 | 3.85 | 2.80 | 2.01 | 1.96 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Current Ratio, Competitors2 | ||||||||||||||||||||||||||||
| AbbVie Inc. | 0.82 | 0.79 | 1.01 | 0.91 | 0.83 | 0.84 | 0.95 | 0.86 | 3.14 | 3.18 | 1.15 | 0.89 | 1.04 | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 1.44 | 1.59 | 1.64 | 1.31 | 1.66 | 1.81 | 2.28 | 2.18 | 1.59 | 1.44 | 2.89 | 2.89 | 2.77 | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 1.32 | 1.52 | 1.47 | 1.54 | 1.56 | 1.58 | 1.67 | 1.47 | 1.66 | 1.60 | 3.83 | 3.88 | 1.93 | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 1.27 | 1.23 | 1.30 | 1.15 | 1.42 | 1.40 | 1.36 | 1.22 | 1.11 | 1.16 | 1.17 | 1.13 | 1.12 | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 1.48 | 1.27 | 1.37 | 1.36 | 1.37 | 1.40 | 3.25 | 2.33 | 3.04 | 3.10 | 2.96 | 3.76 | 3.62 | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 1.39 | 1.35 | 1.34 | 1.39 | 1.28 | 1.21 | 1.48 | 1.25 | 1.31 | 1.26 | 1.26 | 1.33 | 1.44 | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 1.40 | 1.27 | 1.31 | 1.31 | 1.02 | 1.02 | 1.30 | 1.32 | 1.11 | 1.24 | 1.26 | 1.21 | 1.37 | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 1.39 | 1.40 | 1.39 | 1.37 | 1.48 | 1.35 | 1.40 | 1.42 | 1.03 | 0.88 | 0.90 | 1.47 | 1.54 | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 4.76 | 3.56 | 3.71 | 3.57 | 3.12 | 3.63 | 3.89 | 2.12 | 4.21 | 3.67 | 4.03 | 3.88 | 4.58 | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 1.56 | 1.50 | 3.19 | 2.78 | 2.53 | 2.13 | 2.93 | 2.62 | 2.32 | 1.92 | 1.80 | 1.49 | 1.69 | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
1 Q1 2022 Calculation
Current ratio = Current assets ÷ Current liabilities
= 6,837 ÷ 3,034 = 2.25
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Zoetis Inc. current ratio deteriorated from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |
Quick Ratio
Zoetis Inc., quick ratio calculation (quarterly data)
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Cash and cash equivalents | 3,135) | 3,485) | 3,274) | 3,658) | 3,602) | 3,604) | 3,654) | 3,353) | 1,951) | 1,934) | 1,815) | 1,755) | 1,728) | 1,602) | 1,286) | 1,558) | 1,654) | 1,564) | 1,981) | 705) | 629) | |||||||
| Short-term investments | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 12) | 25) | 65) | 99) | 105) | —) | —) | —) | —) | —) | —) | |||||||
| Accounts receivable, less allowance for doubtful accounts | 1,222) | 1,133) | 1,152) | 1,170) | 1,125) | 1,013) | 1,012) | 984) | 965) | 1,086) | 1,030) | 994) | 970) | 1,036) | 929) | 973) | 943) | 998) | 1,009) | 975) | 954) | |||||||
| Total quick assets | 4,357) | 4,618) | 4,426) | 4,828) | 4,727) | 4,617) | 4,666) | 4,337) | 2,916) | 3,020) | 2,857) | 2,774) | 2,763) | 2,737) | 2,320) | 2,531) | 2,597) | 2,562) | 2,990) | 1,680) | 1,583) | |||||||
| Current liabilities | 3,034) | 1,797) | 1,471) | 2,091) | 2,066) | 2,170) | 2,400) | 1,811) | 1,721) | 1,806) | 1,052) | 1,075) | 1,082) | 1,223) | 1,003) | 967) | 1,000) | 1,094) | 1,746) | 1,784) | 1,730) | |||||||
| Liquidity Ratio | ||||||||||||||||||||||||||||
| Quick ratio1 | 1.44 | 2.57 | 3.01 | 2.31 | 2.29 | 2.13 | 1.94 | 2.39 | 1.69 | 1.67 | 2.72 | 2.58 | 2.55 | 2.24 | 2.31 | 2.62 | 2.60 | 2.34 | 1.71 | 0.94 | 0.92 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Quick Ratio, Competitors2 | ||||||||||||||||||||||||||||
| AbbVie Inc. | 0.56 | 0.56 | 0.75 | 0.65 | 0.61 | 0.60 | 0.68 | 0.58 | 2.88 | 2.91 | 0.92 | 0.64 | 0.78 | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 0.90 | 1.06 | 1.19 | 0.86 | 1.16 | 1.30 | 1.65 | 1.60 | 1.10 | 1.01 | 2.28 | 2.41 | 2.37 | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 1.03 | 1.20 | 1.16 | 1.16 | 1.25 | 1.28 | 1.43 | 1.26 | 1.38 | 1.26 | 3.63 | 3.61 | 1.64 | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 0.77 | 0.80 | 0.79 | 0.67 | 0.83 | 0.85 | 0.79 | 0.68 | 0.64 | 0.68 | 0.66 | 0.67 | 0.65 | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 1.06 | 0.95 | 1.01 | 1.05 | 0.99 | 1.08 | 2.93 | 2.09 | 2.78 | 2.86 | 2.74 | 3.41 | 3.32 | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 1.06 | 1.04 | 1.03 | 1.04 | 0.97 | 0.91 | 1.17 | 0.92 | 0.98 | 0.94 | 0.93 | 0.95 | 1.01 | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.84 | 0.73 | 0.78 | 0.75 | 0.58 | 0.58 | 0.77 | 0.84 | 0.66 | 0.78 | 0.80 | 0.75 | 0.88 | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.95 | 1.00 | 0.99 | 0.91 | 0.88 | 0.78 | 0.93 | 0.98 | 0.60 | 0.50 | 0.50 | 0.71 | 0.72 | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 3.95 | 2.98 | 3.03 | 2.92 | 2.39 | 2.86 | 3.02 | 1.61 | 3.38 | 2.81 | 3.14 | 2.99 | 3.66 | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.97 | 1.00 | 2.37 | 1.92 | 1.70 | 1.63 | 2.16 | 1.83 | 1.48 | 1.19 | 0.97 | 0.85 | 0.89 | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
1 Q1 2022 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 4,357 ÷ 3,034 = 1.44
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Zoetis Inc. quick ratio deteriorated from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |
Cash Ratio
Zoetis Inc., cash ratio calculation (quarterly data)
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Cash and cash equivalents | 3,135) | 3,485) | 3,274) | 3,658) | 3,602) | 3,604) | 3,654) | 3,353) | 1,951) | 1,934) | 1,815) | 1,755) | 1,728) | 1,602) | 1,286) | 1,558) | 1,654) | 1,564) | 1,981) | 705) | 629) | |||||||
| Short-term investments | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 12) | 25) | 65) | 99) | 105) | —) | —) | —) | —) | —) | —) | |||||||
| Total cash assets | 3,135) | 3,485) | 3,274) | 3,658) | 3,602) | 3,604) | 3,654) | 3,353) | 1,951) | 1,934) | 1,827) | 1,780) | 1,793) | 1,701) | 1,391) | 1,558) | 1,654) | 1,564) | 1,981) | 705) | 629) | |||||||
| Current liabilities | 3,034) | 1,797) | 1,471) | 2,091) | 2,066) | 2,170) | 2,400) | 1,811) | 1,721) | 1,806) | 1,052) | 1,075) | 1,082) | 1,223) | 1,003) | 967) | 1,000) | 1,094) | 1,746) | 1,784) | 1,730) | |||||||
| Liquidity Ratio | ||||||||||||||||||||||||||||
| Cash ratio1 | 1.03 | 1.94 | 2.23 | 1.75 | 1.74 | 1.66 | 1.52 | 1.85 | 1.13 | 1.07 | 1.74 | 1.66 | 1.66 | 1.39 | 1.39 | 1.61 | 1.65 | 1.43 | 1.13 | 0.40 | 0.36 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Cash Ratio, Competitors2 | ||||||||||||||||||||||||||||
| AbbVie Inc. | 0.23 | 0.28 | 0.43 | 0.30 | 0.31 | 0.30 | 0.33 | 0.25 | 2.50 | 2.56 | 0.61 | 0.32 | 0.38 | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 0.51 | 0.66 | 0.87 | 0.55 | 0.82 | 0.91 | 1.24 | 1.09 | 0.68 | 0.69 | 1.94 | 2.05 | 2.07 | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 0.66 | 0.78 | 0.73 | 0.68 | 0.75 | 0.83 | 1.03 | 0.92 | 0.95 | 0.84 | 3.10 | 3.02 | 0.99 | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 0.19 | 0.26 | 0.28 | 0.22 | 0.26 | 0.29 | 0.30 | 0.20 | 0.14 | 0.21 | 0.15 | 0.20 | 0.19 | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 0.62 | 0.56 | 0.56 | 0.64 | 0.58 | 0.65 | 2.52 | 1.79 | 2.34 | 2.50 | 2.39 | 3.03 | 2.97 | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 0.70 | 0.70 | 0.70 | 0.65 | 0.60 | 0.59 | 0.79 | 0.52 | 0.54 | 0.54 | 0.51 | 0.49 | 0.53 | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.40 | 0.34 | 0.42 | 0.39 | 0.26 | 0.30 | 0.36 | 0.50 | 0.32 | 0.47 | 0.39 | 0.35 | 0.47 | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.61 | 0.73 | 0.71 | 0.61 | 0.51 | 0.47 | 0.64 | 0.70 | 0.31 | 0.26 | 0.25 | 0.40 | 0.39 | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 2.34 | 1.45 | 1.56 | 1.05 | 1.09 | 1.33 | 1.29 | 0.85 | 1.95 | 1.53 | 1.63 | 1.56 | 2.14 | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.23 | 0.33 | 1.55 | 1.01 | 0.80 | 1.00 | 1.21 | 0.97 | 0.54 | 0.39 | 0.22 | 0.30 | 0.19 | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
1 Q1 2022 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 3,135 ÷ 3,034 = 1.03
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Zoetis Inc. cash ratio deteriorated from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |